Search

Your search keyword '"Lambe, Mats"' showing total 1,482 results
Start Over Author "Lambe, Mats"
1,482 results on '"Lambe, Mats"'

8. Were cancer patients worse off than the general population during the COVID-19 pandemic? A population-based study from Norway, Denmark and Iceland during the pre-vaccination era

Author

Johansson, Anna L.V., Skog, Anna, Johannesen, Tom Børge, Myklebust, Tor Åge, Skovlund, Charlotte Wessel, Mørch, Lina Steinrud, Friis, Søren, Gamborg, Mads, Kristiansen, Marnar Fríðheim, Pettersson, David, Ólafsdóttir, Elínborg J., Birgisson, Helgi, Palsson, Runolfur, Eythorsson, Elias, Irenaeus, Sandra, Lambe, Mats, and Ursin, Giske

Published
2023
Full Text
View/download PDF

9. Socioeconomic inequality in prostate cancer diagnostics, primary treatment, rehabilitation, and mortality in Sweden.

Author

Strömberg, Ulf, Berglund, Anders, Carlsson, Stefan, Thellenberg Karlsson, Camilla, Lambe, Mats, Lissbrant, Ingela Franck, Stattin, Pär, and Bratt, Ola

Subjects
PROSTATE cancer, HEALTH equity, PROSTATE cancer patients, MAGNETIC resonance imaging, NATIONAL health services, INCOME, ENDORECTAL ultrasonography
Abstract

We designed a nationwide study to investigate the association between socioeconomic factors (household income and education) and different aspects of prostate cancer care, considering both individual‐ and neighbourhood‐level variables. Data were obtained from Prostate Cancer data Base Sweden (PCBaSe), a research database with data from several national health care registers including clinical characteristics and treatments for nearly all men diagnosed with prostate cancer in Sweden. Four outcomes were analysed: use of pre‐biopsy magnetic resonance imaging (MRI) in 2018–2020 (n = 11,843), primary treatment of high‐risk non‐metastatic disease in 2016–2020 (n = 6633), rehabilitation (≥2 dispensed prescriptions for erectile dysfunction within 1 year from surgery in 2016–2020, n = 6505), and prostate cancer death in 7770 men with high‐risk non‐metastatic disease diagnosed in 2010–2016. Unadjusted and adjusted odds and hazard ratios (OR/HRs) with 95% confidence intervals (CIs) were calculated. Adjusted odds ratio (ORs) comparing low versus high individual education were 0.74 (95% CI 0.66–0.83) for pre‐biopsy MRI, 0.66 (0.54–0.81) for primary treatment, and 0.82 (0.69–0.97) for rehabilitation. HR gradients for prostate cancer death were significant on unadjusted analysis only (low vs. high individual education HR 1.41, 95% CI 1.17–1.70); co‐variate adjustments markedly attenuated the gradients (low vs. high individual education HR 1.10, 95% CI 0.90–1.35). Generally, neighbourhood‐level analyses showed weaker gradients over the socioeconomic strata, except for pre‐biopsy MRI. Socioeconomic factors influenced how men were diagnosed with prostate cancer in Sweden but had less influence on subsequent specialist care. Neighbourhood‐level socioeconomic data are more useful for evaluating inequality in diagnostics than in later specialist care. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Have the recent advancements in cancer therapy and survival benefitted patients of all age groups across the Nordic countries? NORDCAN survival analyses 2002-2021

Author

Johansson, Anna L.V., primary, Kønig, Simon M., additional, Larønningen, Siri, additional, Engholm, Gerda, additional, Kroman, Niels, additional, Seppä, Karri, additional, Malila, Nea, additional, Steig, Bjarni Á., additional, Gudmundsdóttir, Eva Maria, additional, Ólafsdóttir, Elínborg J., additional, Lundberg, Frida E., additional, Andersson, Therese M.-L., additional, Lambert, Paul C., additional, Lambe, Mats, additional, Pettersson, David, additional, Aagnes, Bjarte, additional, Friis, Søren, additional, and Storm, Hans, additional

Published
2024
Full Text
View/download PDF

19. Impact of variation in cancer registration practice on observed international cancer survival differences between International Cancer Benchmarking Partnership (ICBP) jurisdictions

Author

Eden, Michael, Harrison, Samantha, Griffin, Michelle, Lambe, Mats, Pettersson, David, Gavin, Anna, Brewster, David H., Lin, Yulan, Johannesen, Tom B., Milne, Roger L., Farrugia, Helen, Nishri, Diane, King, Mary-Jane, Huws, Dyfed W, Warlow, Janet, Turner, Donna, Earle, Craig C., Peake, Michael, and Rashbass, Jem

Published
2019
Full Text
View/download PDF

32. CCR Translation for This Article from A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin κ C as a Compatible Prognostic Marker in Human Solid Tumors

Author

Schmidt, Marcus, primary, Hellwig, Birte, primary, Hammad, Seddik, primary, Othman, Amnah, primary, Lohr, Miriam, primary, Chen, Zonglin, primary, Boehm, Daniel, primary, Gebhard, Susanne, primary, Petry, Ilka, primary, Lebrecht, Antje, primary, Cadenas, Cristina, primary, Marchan, Rosemarie, primary, Stewart, Joanna D., primary, Solbach, Christine, primary, Holmberg, Lars, primary, Edlund, Karolina, primary, Kultima, Hanna Göransson, primary, Rody, Achim, primary, Berglund, Anders, primary, Lambe, Mats, primary, Isaksson, Anders, primary, Botling, Johan, primary, Karn, Thomas, primary, Müller, Volkmar, primary, Gerhold-Ay, Aslihan, primary, Cotarelo, Christina, primary, Sebastian, Martin, primary, Kronenwett, Ralf, primary, Bojar, Hans, primary, Lehr, Hans-Anton, primary, Sahin, Ugur, primary, Koelbl, Heinz, primary, Gehrmann, Mathias, primary, Micke, Patrick, primary, Rahnenführer, Jörg, primary, and Hengstler, Jan G., primary

Published
2023
Full Text
View/download PDF

33. Data from Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer

Author

Lu, Donghao, primary, Sinnott, Jennifer A., primary, Valdimarsdóttir, Unnur, primary, Fang, Fang, primary, Gerke, Travis, primary, Tyekucheva, Svitlana, primary, Fiorentino, Michelangelo, primary, Lambe, Mats, primary, Sesso, Howard D., primary, Sweeney, Christopher J., primary, Wilson, Kathryn M., primary, Giovannucci, Edward L., primary, Loda, Massimo, primary, Mucci, Lorelei A., primary, and Fall, Katja, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Materials and Methods from A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin κ C as a Compatible Prognostic Marker in Human Solid Tumors

Author

Schmidt, Marcus, primary, Hellwig, Birte, primary, Hammad, Seddik, primary, Othman, Amnah, primary, Lohr, Miriam, primary, Chen, Zonglin, primary, Boehm, Daniel, primary, Gebhard, Susanne, primary, Petry, Ilka, primary, Lebrecht, Antje, primary, Cadenas, Cristina, primary, Marchan, Rosemarie, primary, Stewart, Joanna D., primary, Solbach, Christine, primary, Holmberg, Lars, primary, Edlund, Karolina, primary, Kultima, Hanna Göransson, primary, Rody, Achim, primary, Berglund, Anders, primary, Lambe, Mats, primary, Isaksson, Anders, primary, Botling, Johan, primary, Karn, Thomas, primary, Müller, Volkmar, primary, Gerhold-Ay, Aslihan, primary, Cotarelo, Christina, primary, Sebastian, Martin, primary, Kronenwett, Ralf, primary, Bojar, Hans, primary, Lehr, Hans-Anton, primary, Sahin, Ugur, primary, Koelbl, Heinz, primary, Gehrmann, Mathias, primary, Micke, Patrick, primary, Rahnenführer, Jörg, primary, and Hengstler, Jan G., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figures 1-11 from A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin κ C as a Compatible Prognostic Marker in Human Solid Tumors

Author

Schmidt, Marcus, primary, Hellwig, Birte, primary, Hammad, Seddik, primary, Othman, Amnah, primary, Lohr, Miriam, primary, Chen, Zonglin, primary, Boehm, Daniel, primary, Gebhard, Susanne, primary, Petry, Ilka, primary, Lebrecht, Antje, primary, Cadenas, Cristina, primary, Marchan, Rosemarie, primary, Stewart, Joanna D., primary, Solbach, Christine, primary, Holmberg, Lars, primary, Edlund, Karolina, primary, Kultima, Hanna Göransson, primary, Rody, Achim, primary, Berglund, Anders, primary, Lambe, Mats, primary, Isaksson, Anders, primary, Botling, Johan, primary, Karn, Thomas, primary, Müller, Volkmar, primary, Gerhold-Ay, Aslihan, primary, Cotarelo, Christina, primary, Sebastian, Martin, primary, Kronenwett, Ralf, primary, Bojar, Hans, primary, Lehr, Hans-Anton, primary, Sahin, Ugur, primary, Koelbl, Heinz, primary, Gehrmann, Mathias, primary, Micke, Patrick, primary, Rahnenführer, Jörg, primary, and Hengstler, Jan G., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Table 4 from Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation

Author

Botling, Johan, primary, Edlund, Karolina, primary, Lohr, Miriam, primary, Hellwig, Birte, primary, Holmberg, Lars, primary, Lambe, Mats, primary, Berglund, Anders, primary, Ekman, Simon, primary, Bergqvist, Michael, primary, Pontén, Fredrik, primary, König, André, primary, Fernandes, Oswaldo, primary, Karlsson, Mats, primary, Helenius, Gisela, primary, Karlsson, Christina, primary, Rahnenführer, Jörg, primary, Hengstler, Jan G, primary, and Micke, Patrick, primary

Published
2023
Full Text
View/download PDF

37. Supplementary Table 1 from Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation

Author

Botling, Johan, primary, Edlund, Karolina, primary, Lohr, Miriam, primary, Hellwig, Birte, primary, Holmberg, Lars, primary, Lambe, Mats, primary, Berglund, Anders, primary, Ekman, Simon, primary, Bergqvist, Michael, primary, Pontén, Fredrik, primary, König, André, primary, Fernandes, Oswaldo, primary, Karlsson, Mats, primary, Helenius, Gisela, primary, Karlsson, Christina, primary, Rahnenführer, Jörg, primary, Hengstler, Jan G, primary, and Micke, Patrick, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Table S1 from Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer

Author

Lu, Donghao, primary, Sinnott, Jennifer A., primary, Valdimarsdóttir, Unnur, primary, Fang, Fang, primary, Gerke, Travis, primary, Tyekucheva, Svitlana, primary, Fiorentino, Michelangelo, primary, Lambe, Mats, primary, Sesso, Howard D., primary, Sweeney, Christopher J., primary, Wilson, Kathryn M., primary, Giovannucci, Edward L., primary, Loda, Massimo, primary, Mucci, Lorelei A., primary, and Fall, Katja, primary

Published
2023
Full Text
View/download PDF

39. Supplementary Discussion from Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation

Author

Botling, Johan, primary, Edlund, Karolina, primary, Lohr, Miriam, primary, Hellwig, Birte, primary, Holmberg, Lars, primary, Lambe, Mats, primary, Berglund, Anders, primary, Ekman, Simon, primary, Bergqvist, Michael, primary, Pontén, Fredrik, primary, König, André, primary, Fernandes, Oswaldo, primary, Karlsson, Mats, primary, Helenius, Gisela, primary, Karlsson, Christina, primary, Rahnenführer, Jörg, primary, Hengstler, Jan G, primary, and Micke, Patrick, primary

Published
2023
Full Text
View/download PDF

40. Supplementary Tables 1-3 from A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin κ C as a Compatible Prognostic Marker in Human Solid Tumors

Author

Schmidt, Marcus, primary, Hellwig, Birte, primary, Hammad, Seddik, primary, Othman, Amnah, primary, Lohr, Miriam, primary, Chen, Zonglin, primary, Boehm, Daniel, primary, Gebhard, Susanne, primary, Petry, Ilka, primary, Lebrecht, Antje, primary, Cadenas, Cristina, primary, Marchan, Rosemarie, primary, Stewart, Joanna D., primary, Solbach, Christine, primary, Holmberg, Lars, primary, Edlund, Karolina, primary, Kultima, Hanna Göransson, primary, Rody, Achim, primary, Berglund, Anders, primary, Lambe, Mats, primary, Isaksson, Anders, primary, Botling, Johan, primary, Karn, Thomas, primary, Müller, Volkmar, primary, Gerhold-Ay, Aslihan, primary, Cotarelo, Christina, primary, Sebastian, Martin, primary, Kronenwett, Ralf, primary, Bojar, Hans, primary, Lehr, Hans-Anton, primary, Sahin, Ugur, primary, Koelbl, Heinz, primary, Gehrmann, Mathias, primary, Micke, Patrick, primary, Rahnenführer, Jörg, primary, and Hengstler, Jan G., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Figure 1 from Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation

Author

Botling, Johan, primary, Edlund, Karolina, primary, Lohr, Miriam, primary, Hellwig, Birte, primary, Holmberg, Lars, primary, Lambe, Mats, primary, Berglund, Anders, primary, Ekman, Simon, primary, Bergqvist, Michael, primary, Pontén, Fredrik, primary, König, André, primary, Fernandes, Oswaldo, primary, Karlsson, Mats, primary, Helenius, Gisela, primary, Karlsson, Christina, primary, Rahnenführer, Jörg, primary, Hengstler, Jan G, primary, and Micke, Patrick, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Table 3 from Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation

Author

Botling, Johan, primary, Edlund, Karolina, primary, Lohr, Miriam, primary, Hellwig, Birte, primary, Holmberg, Lars, primary, Lambe, Mats, primary, Berglund, Anders, primary, Ekman, Simon, primary, Bergqvist, Michael, primary, Pontén, Fredrik, primary, König, André, primary, Fernandes, Oswaldo, primary, Karlsson, Mats, primary, Helenius, Gisela, primary, Karlsson, Christina, primary, Rahnenführer, Jörg, primary, Hengstler, Jan G, primary, and Micke, Patrick, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Figure 4 from Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation

Author

Botling, Johan, primary, Edlund, Karolina, primary, Lohr, Miriam, primary, Hellwig, Birte, primary, Holmberg, Lars, primary, Lambe, Mats, primary, Berglund, Anders, primary, Ekman, Simon, primary, Bergqvist, Michael, primary, Pontén, Fredrik, primary, König, André, primary, Fernandes, Oswaldo, primary, Karlsson, Mats, primary, Helenius, Gisela, primary, Karlsson, Christina, primary, Rahnenführer, Jörg, primary, Hengstler, Jan G, primary, and Micke, Patrick, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Table 2 from Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation

Author

Botling, Johan, primary, Edlund, Karolina, primary, Lohr, Miriam, primary, Hellwig, Birte, primary, Holmberg, Lars, primary, Lambe, Mats, primary, Berglund, Anders, primary, Ekman, Simon, primary, Bergqvist, Michael, primary, Pontén, Fredrik, primary, König, André, primary, Fernandes, Oswaldo, primary, Karlsson, Mats, primary, Helenius, Gisela, primary, Karlsson, Christina, primary, Rahnenführer, Jörg, primary, Hengstler, Jan G, primary, and Micke, Patrick, primary

Published
2023
Full Text
View/download PDF

45. Supplementary Table 5 from Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation

Author

Botling, Johan, primary, Edlund, Karolina, primary, Lohr, Miriam, primary, Hellwig, Birte, primary, Holmberg, Lars, primary, Lambe, Mats, primary, Berglund, Anders, primary, Ekman, Simon, primary, Bergqvist, Michael, primary, Pontén, Fredrik, primary, König, André, primary, Fernandes, Oswaldo, primary, Karlsson, Mats, primary, Helenius, Gisela, primary, Karlsson, Christina, primary, Rahnenführer, Jörg, primary, Hengstler, Jan G, primary, and Micke, Patrick, primary

Published
2023
Full Text
View/download PDF

46. Supplementary Figure 3 from Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation

Author

Botling, Johan, primary, Edlund, Karolina, primary, Lohr, Miriam, primary, Hellwig, Birte, primary, Holmberg, Lars, primary, Lambe, Mats, primary, Berglund, Anders, primary, Ekman, Simon, primary, Bergqvist, Michael, primary, Pontén, Fredrik, primary, König, André, primary, Fernandes, Oswaldo, primary, Karlsson, Mats, primary, Helenius, Gisela, primary, Karlsson, Christina, primary, Rahnenführer, Jörg, primary, Hengstler, Jan G, primary, and Micke, Patrick, primary

Published
2023
Full Text
View/download PDF

47. Supplementary Figure 2 from Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation

Author

Botling, Johan, primary, Edlund, Karolina, primary, Lohr, Miriam, primary, Hellwig, Birte, primary, Holmberg, Lars, primary, Lambe, Mats, primary, Berglund, Anders, primary, Ekman, Simon, primary, Bergqvist, Michael, primary, Pontén, Fredrik, primary, König, André, primary, Fernandes, Oswaldo, primary, Karlsson, Mats, primary, Helenius, Gisela, primary, Karlsson, Christina, primary, Rahnenführer, Jörg, primary, Hengstler, Jan G, primary, and Micke, Patrick, primary

Published
2023
Full Text
View/download PDF

49. Therapy-related MDS dissected based on primary disease and treatment-a nationwide perspective

Author

Berggren, Daniel Moreno, Garelius, Hege, Willner Hjelm, Petter, Nilsson, Lars, Rasmussen, Bengt, Weibull, Caroline E., Lambe, Mats, Lehmann, Soren, Hellstrom-Lindberg, Eva, Jadersten, Martin, Ejerblad, Elisabeth, Berggren, Daniel Moreno, Garelius, Hege, Willner Hjelm, Petter, Nilsson, Lars, Rasmussen, Bengt, Weibull, Caroline E., Lambe, Mats, Lehmann, Soren, Hellstrom-Lindberg, Eva, Jadersten, Martin, and Ejerblad, Elisabeth

Abstract

In this population-based study, we aimed to characterize and compare subgroups of therapy-related Myelodysplastic syndromes (t-MDS) and define the implications of type of previous treatment and primary disease. We combined data from MDS patients, diagnosed between 2009 and 2017 (n = 2705), in the nationwide Swedish MDS register, with several health registers. Furthermore, using matched population controls, we investigated the prevalence of antecedent malignancies in MDS patients in comparison with the general population. This first ever nationwide study on t-MDS confirms a shorter median survival for t-MDS compared to de novo MDS (15.8 months vs 31.1 months, p < 0.001). T-MDS patients previously treated with radiation only had disease characteristics with a striking resemblance to de novo-MDS, in sharp contrast to patients treated with chemotherapy who had a significantly higher risk profile. IPSS-R and the WHO classification differentiated t-MDS into different risk groups. As compared with controls, MDS patients had a six-fold increased prevalence of a previous hematological malignancy but only a 34% increased prevalence of a previous solid tumor. T-MDS patients with a previous hematological malignancy had a dismal prognosis, due both to mortality related to their primary disease and to high-risk MDS.

Published
2023
Full Text
View/download PDF

50. Were cancer patients worse off than the general population during the COVID-19 pandemic? : A population-based study from Norway, Denmark and Iceland during the pre-vaccination era

Author

Johansson, Anna L., V, Skog, Anna, Johannesen, Tom Borge, Myklebust, Tor age, Skovlund, Charlotte Wessel, Morch, Lina Steinrud, Friis, Soren, Gamborg, Mads, Kristiansen, Marnar Frioheim, Pettersson, David, Olafsdottir, Elinborg J., Birgisson, Helgi, Palsson, Runolfur, Eythorsson, Elias, Irenaeus, Sandra, Lambe, Mats, Ursin, Giske, Johansson, Anna L., V, Skog, Anna, Johannesen, Tom Borge, Myklebust, Tor age, Skovlund, Charlotte Wessel, Morch, Lina Steinrud, Friis, Soren, Gamborg, Mads, Kristiansen, Marnar Frioheim, Pettersson, David, Olafsdottir, Elinborg J., Birgisson, Helgi, Palsson, Runolfur, Eythorsson, Elias, Irenaeus, Sandra, Lambe, Mats, and Ursin, Giske

Abstract

Background In a population-based setting, we investigated the risks of testing positive for SARS-CoV-2 and developing severe COVID-19 outcomes among cancer patients compared with the general population.Methods In nationwide cohorts, we identified all individuals in Norway, Denmark and Iceland who tested positive for SARS-CoV-2 or had a severe COVID-19 outcome (hospitalisation, intensive care, and death) from March until December 2020, using data from national health registries. We estimated standardised incidence ratios (SIRs) with 95% confidence intervals (CIs) comparing cancer patients with the general population.Findings During the first wave of the pandemic, cancer patients in Norway and Denmark had higher risks of testing SARS-CoV-2 positive compared to the general population. Throughout 2020, recently treated cancer patients were more likely to test SARS-CoV-2 positive. In Iceland, cancer patients experienced no increased risk of testing positive. The risk of COVID-19-related hospitalisation was higher among cancer patients diagnosed within one year of hospitalisation (Norway: SIR = 2.43, 95% CI 1.89-3.09; Denmark: 2.23, 1.96-2.54) and within five years (Norway: 1.58, 1.35-1.83; Denmark: 1.54, 1.42-1.66). Risks were higher in recently treated cancer patients and in those diagnosed with haematologic malignancies, colorectal or lung cancer. Risks of COVID-19-related intensive care and death were higher among cancer patients. Interpretation Cancer patients were at increased risk of testing positive for SARS-CoV-2 during the first pandemic wave when testing availability was limited, while relative risks of severe COVID-19 outcomes remained increased in cancer patients throughout 2020. Recent cancer treatment and haematologic malignancy were the strongest risk factors.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results